Opinion

Video

CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

Author(s):

Benjamin Garmezy, MD,Martin H. Voss, MD

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

Related Videos
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Yousef Zakharia, MD
Nazli Dizman, MD
Related Content
Toni Choueiri, MD
January 28th 2025

NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

The OncFive: OncLive's Top Oncology Articles for the Week of 1/19
January 25th 2025

The OncFive: Top Oncology Articles for the Week of 1/19

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

Felix Y. Feng, MD
January 22nd 2025

Felix Y. Feng, MD, Leading Radiation Oncologist and Genitourinary Cancer Researcher, Dies at 48

Eric Winer, MD
January 22nd 2025

2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer